Pediatric cancer biotech Y-mAbs Therapeutics Inc. priced its initial public offering late Thursday at $16 a share, selling 6 million shares to raise $96 million. Shares will start trading later Friday on Nasdaq, under the ticker symbol “YMAB”. BofA Merrill Lynch and Cowen were joint bookrunners on the deal with Canaccord Genuity acting as lead manager and BTIG acting as co-manager.
Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.
Latest posts by Market Watch (see all)
- The Wall Street Journal: Interior Secretary Zinke’s travel violated policy, report says - October 18, 2018
- Asia Markets: Chinese stocks bounce back despite disappointing GDP numbers - October 18, 2018
- The Wall Street Journal: China’s growth slows to weakest pace since financial crisis - October 18, 2018